# HERTHENA-Lung02 (NCT05338970)

> HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05338970
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Nonsquamous Non-small Cell Lung Cancer; EGFR L858R; EGFR Exon 19 Deletion
- Interventions: Patritumab Deruxtecan; Platinum-based chemotherapy
- Enrollment: 586
- Primary outcome: Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 43
- YouTube: 13
- Podcasts: 12

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=herthena-lung02-nct05338970

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05338970", "email": "<work email>"}; the inbox owner confirms by the emailed link.